Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S298-S301

  Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HBV; HCC; Interferon; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; NUCLEOSIDE; NUCLEOTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CHEMOPROPHYLAXIS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; PRIMARY PREVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY; REHABILITATION; SELECTION BIAS; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; POLYETHYLENE GLYCOLS; PRIMARY PREVENTION; RECOMBINANT PROTEINS; SELECTION BIAS; TERTIARY PREVENTION;

EID: 77953715548     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60520-8     Document Type: Article

References (30)

1. Lok ASF, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
2. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50:227-242. European Association for the Study of the Liver.
3. Craxi A, Cammà C Prevention of hepatocellular carcinoma. Clin Liver Dis 2005, 9:329-346.
4. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-1077.
5. Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16:265-271.
6. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996, 24:141-147.
7. Oon CJ Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992, 31(Suppl):S137-S142.
8. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427.
9. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-975.
10. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. Hepatology 2007, 46:45-52.
11. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139-145.
12. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004, 39:804-810.
13. Brunetto M, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263-270.
14. Papatheodoridis GV, Manesis E, Hadzyiannis SJ The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306-313.
15. Lampertico P, Vigano M, Manenti E, et al. Low resistance to Ade-fovir combined with Lamivudine: A 3 year study of 145 Lamivudine resistant hepatitis B patients. Gastroenterology 2007, 133:1445-1451.
16. Yuen MF, Tanaka Y, Shinkai N, et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008, 57:98-102.
17. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. N Engl J Med 2004, 351:1521-1531.
18. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004, 40:883-891.
19. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicen-ter retrospective study of 2795 patients. Hepatol Res 2005, 32:173-184.
20. Lampertico P, Vigano M, Manenti E, et al. Five years of sequential lam to lam + adv therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. J Hepatol 2006, 44S2:S38.
21. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009, [Epub ahead of print]. 10.1016/j.jhep.2009.07.009.
22. Llovet JM, Bruix J Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl l):S20-S27.
23. Oon CJ, Chen WN Lymphoblastoid alpha-interferon in the prevention of hepatocellular carcinoma (HCC) in high-risk HBsAg-positive resected cirrhotic HCC cases: a 14-year follow-up. Cancer Invest 2003, 21:394-399.
24. Lin SM, Tai DI, Chien RN, et al. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hep 2004, 11:349-357.
25. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon a treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132:458-465.
26. Someya T, Ikeda K, Saitoh S, et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006, 41:1206-1213.
27. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007, 245:831-842.
28. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33:424-432.
29. Fontana RJ Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003, 23:89-100.
30. Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008, 48:1070-1078.